These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 35442407)

  • 41. Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients.
    Calvo-Río V; Blanco R; Beltrán E; Sánchez-Bursón J; Mesquida M; Adán A; Hernandez MV; Hernandez Garfella M; Valls Pascual E; Martínez-Costa L; Sellas-Fernández A; Cordero Coma M; Díaz-Llopis M; Gallego R; Salom D; García Serrano JL; Ortego N; Herreras JM; Fonollosa A; García-Aparicio AM; Maíz O; Blanco A; Torre I; Fernández-Espartero C; Jovani V; Peiteado-Lopez D; Pato E; Cruz J; Fernández-Cid C; Aurrecoechea E; García M; Caracuel MA; Montilla C; Atanes A; Hernandez FF; Insua S; González-Suárez S; Sánchez-Andrade A; Gamero F; Linares L; Romero-Bueno F; García AJ; Almodovar R; Minguez E; Carrasco Cubero C; Olive A; Vázquez J; Ruiz Moreno O; Jiménez-Zorzo F; Manero J; Muñoz Fernández S; Rueda-Gotor J; González-Gay MA
    Rheumatology (Oxford); 2014 Dec; 53(12):2223-31. PubMed ID: 24996907
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Emerging drugs for the treatment of uveitis.
    Leung TG; Thorne JE
    Expert Opin Emerg Drugs; 2013 Dec; 18(4):513-21. PubMed ID: 24274613
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Azathioprine for ocular inflammatory diseases.
    Pasadhika S; Kempen JH; Newcomb CW; Liesegang TL; Pujari SS; Rosenbaum JT; Thorne JE; Foster CS; Jabs DA; Levy-Clarke GA; Nussenblatt RB; Suhler EB
    Am J Ophthalmol; 2009 Oct; 148(4):500-509.e2. PubMed ID: 19570522
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Association between Immunosuppressive Drugs and Coronavirus Disease 2019 Outcomes in Patients with Noninfectious Uveitis in a Large US Claims Database.
    Sun Y; Miller DC; Akpandak I; Chen EM; Arnold BF; Acharya NR
    Ophthalmology; 2022 Oct; 129(10):1096-1106. PubMed ID: 35588945
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients.
    Díaz-Llopis M; Salom D; Garcia-de-Vicuña C; Cordero-Coma M; Ortega G; Ortego N; Suarez-de-Figueroa M; Rio-Pardo MJ; Fernandez-Cid C; Fonollosa A; Blanco R; Garcia-Aparicio AM; Benitez-Del-Castillo JM; Olea JL; Arevalo JF
    Ophthalmology; 2012 Aug; 119(8):1575-81. PubMed ID: 22525047
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment of noninfectious uveitis.
    Ferreira LB; Farrall AL; Furtado JM; Smith JR
    Arq Bras Oftalmol; 2021; 84(6):610-621. PubMed ID: 34431877
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Uveitis Therapy: The Corticosteroid Options.
    Valdes LM; Sobrin L
    Drugs; 2020 Jun; 80(8):765-773. PubMed ID: 32350761
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intravitreal Sirolimus for Noninfectious Uveitis: A Phase III Sirolimus Study Assessing Double-masKed Uveitis TReAtment (SAKURA).
    Nguyen QD; Merrill PT; Clark WL; Banker AS; Fardeau C; Franco P; LeHoang P; Ohno S; Rathinam SR; Thurau S; Abraham A; Wilson L; Yang Y; Shams N;
    Ophthalmology; 2016 Nov; 123(11):2413-2423. PubMed ID: 27692526
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and Safety of Adalimumab Therapy for the Treatment of Non-infectious Uveitis: Efficacy comparison among Uveitis Aetiologies.
    Hiyama T; Harada Y; Kiuchi Y
    Ocul Immunol Inflamm; 2022 May; 30(4):951-958. PubMed ID: 33560160
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial.
    Tugal-Tutkun I; Mudun A; Urgancioglu M; Kamali S; Kasapoglu E; Inanc M; Gül A
    Arthritis Rheum; 2005 Aug; 52(8):2478-84. PubMed ID: 16052571
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Methotrexate for ocular inflammatory diseases.
    Gangaputra S; Newcomb CW; Liesegang TL; Kaçmaz RO; Jabs DA; Levy-Clarke GA; Nussenblatt RB; Rosenbaum JT; Suhler EB; Thorne JE; Foster CS; Kempen JH;
    Ophthalmology; 2009 Nov; 116(11):2188-98.e1. PubMed ID: 19748676
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy, safety and cost-effectiveness of methotrexate, adalimumab or their combination in non-infectious non-anterior uveitis: a protocol for a multicentre, randomised, parallel three arms, active-controlled, phase III open label with blinded outcome assessment study.
    Rivas AB; Lopez-Picado A; Calamia V; Carreño E; Cocho L; Cordero-Coma M; Fonollosa A; Francisco Hernandez FM; Garcia-Aparicio A; Garcia-Gonzalez J; Mondejar JJ; Lojo-Oliveira L; Martínez-Costa L; Munoz S; Peiteado D; Pinto JA; Rodriguez-Lozano B; Pato E; Diaz-Valle D; Molina E; Tebar LA; Rodriguez-Rodriguez L;
    BMJ Open; 2022 Mar; 12(3):e051378. PubMed ID: 35318229
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy of Adalimumab in Non-Infectious Uveitis Across Different Etiologies: A Post Hoc Analysis of the VISUAL I and VISUAL II Trials.
    Merrill PT; Vitale A; Zierhut M; Goto H; Kron M; Song AP; Pathai S; Fortin E
    Ocul Immunol Inflamm; 2021 Nov; 29(7-8):1569-1575. PubMed ID: 32469621
    [No Abstract]   [Full Text] [Related]  

  • 54. Long-Term Follow-up of Patients With Uveitis Treated With Adalimumab: Response Rates and Reasons for Discontinuation of Therapy.
    Eurelings LEM; Missotten TOAR; van Velthoven MEJ; van Daele PLA; van Laar JAM; van Hagen PM; Thiadens AAHJ; Rombach SM
    Am J Ophthalmol; 2022 Aug; 240():194-204. PubMed ID: 35314190
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dexamethasone for ocular inflammation.
    Saraiya NV; Goldstein DA
    Expert Opin Pharmacother; 2011 May; 12(7):1127-31. PubMed ID: 21457057
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial).
    Ramanan AV; Dick AD; Benton D; Compeyrot-Lacassagne S; Dawoud D; Hardwick B; Hickey H; Hughes D; Jones A; Woo P; Edelsten C; Beresford MW;
    Trials; 2014 Jan; 15():14. PubMed ID: 24405833
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Discontinuing adalimumab in patients with controlled juvenile idiopathic arthritis-associated uveitis (ADJUST-Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Stopping Trial): study protocol for a randomised controlled trial.
    Acharya NR; Ebert CD; Kelly NK; Porco TC; Ramanan AV; Arnold BF;
    Trials; 2020 Oct; 21(1):887. PubMed ID: 33109240
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Anti-Tumor Necrosis Factor Treatment in the Management of Pediatric Noninfectious Uveitis: Infliximab Versus Adalimumab.
    Ucan Gunduz G; Yalcinbayir O; Cekic S; Yildiz M; Kilic SS
    J Ocul Pharmacol Ther; 2021 May; 37(4):236-240. PubMed ID: 33512278
    [No Abstract]   [Full Text] [Related]  

  • 59. Adalimumab for non-infectious uveitis: is it cost-effective?
    Bermejo I; Squires H; Poku EN; Cooper K; Stevens JW; Hamilton J; Wong R; Pearce I; Quhill FM; Denniston AK
    Br J Ophthalmol; 2019 Nov; 103(11):1633-1638. PubMed ID: 30728124
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacologic Treatment of Noninfectious Uveitis.
    Knickelbein JE; Armbrust KR; Kim M; Sen HN; Nussenblatt RB
    Handb Exp Pharmacol; 2017; 242():231-268. PubMed ID: 27848029
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.